Archive for April, 2008
WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–May 1, 2008 - Merck & Co., Inc. said today it has extended to June 30, 2008, the enrollment deadline for U.S. eligible claimants with cases filed or tolled by Nov. 9, 2007 wishing to be part of the program … Originally Syndicated via RSS from vioxx - Live Search News
28/04/2008 13:03:00 Business Wire US8668101046 MediConnect Global, Inc. today urged Merck Vioxx Settlement claimants to order the retrieval of their pharmacy, medical and event records (PME records) as soon as possible. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
MediConnect Global, Inc. today urged Merck Vioxx Settlement claimants to order the retrieval of their pharmacy, medical and event records (PME records) as soon as possible. PME records are required in the Claims Package that must be submitted before a looming July 1st deadline. www.mediconnect.net Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
David Egilman ‘74 MD’78 teaches community health at the Alpert Medical School. But once in a while, he dabbles in ethics. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
A Merck’s internal communication talks of the drug being associated with an increased risk of causing deaths Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Another paper published in the same issue of the Journal of the American Medical Association (JAMA) lands the second blow on Merck, the American drug company. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Lyle Palmer has plans for a #28;ludicrously ambitious#29; gene#19;disease research project. Bijal Trivedi reports on the trials at Joondalup. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Shareholders of Merck questioned executives yesterday about the drugmaker’s low stock price and recent controversies about its credibility. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Shareholders of Merck & Co. questioned executives Tuesday about the drugmaker’s low stock price and recent controversies about its credibility. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx
Merck and Schering have received letters from various federal and state agencies seeking information related to the ENHANCE trials as well as information related to the promotion of Vytorin. Originally Syndicated via RSS from Yahoo! News Search Results for vioxx |
|